Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free AGY Stock Alerts

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 8.90 +0.40 (+4.71%)
As of 09:59 AM Eastern
Compare

AGY vs. INDV, HCM, AMYT, APH, and ANCR

Should you buy Allergy Therapeutics stock or one of its competitors? MarketBeat compares Allergy Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allergy Therapeutics include Indivior (INDV), HUTCHMED (HCM), Amryt Pharma (AMYT), Alliance Pharma (APH), and Animalcare Group (ANCR). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Allergy Therapeutics compare to Indivior?

Indivior (LON:INDV) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Indivior had 1 more articles in the media than Allergy Therapeutics. MarketBeat recorded 1 mentions for Indivior and 0 mentions for Allergy Therapeutics. Indivior's average media sentiment score of 0.67 beat Allergy Therapeutics' score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company Overall Sentiment
Indivior Positive
Allergy Therapeutics Neutral

86.0% of Indivior shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 3.4% of Indivior shares are held by insiders. Comparatively, 3.5% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Indivior has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.891, indicating that its stock price is 11% less volatile than the broader market.

Indivior has a net margin of 14.30% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior14.30% -41.70% 2.37%
Allergy Therapeutics -85.46%409.00%-34.76%

Indivior has higher revenue and earnings than Allergy Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B1.38-£2.36M-£1.21N/A
Allergy Therapeutics£57.29M9.84-£52.59M-£0.97N/A

Summary

Indivior beats Allergy Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to HUTCHMED?

Allergy Therapeutics (LON:AGY) and HUTCHMED (LON:HCM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of HUTCHMED shares are owned by institutional investors. 3.5% of Allergy Therapeutics shares are owned by insiders. Comparatively, 2.8% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
HUTCHMED Neutral

Allergy Therapeutics has higher earnings, but lower revenue than HUTCHMED. Allergy Therapeutics is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M9.84-£52.59M-£0.97N/A
HUTCHMED£548.51M2.73-£52.98M£53.003.28

Allergy Therapeutics has a beta of 0.891, meaning that its share price is 11% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.453, meaning that its share price is 55% less volatile than the broader market.

HUTCHMED has a net margin of 104.77% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
HUTCHMED 104.77%41.38%-5.90%

Summary

HUTCHMED beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Amryt Pharma?

Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amryt Pharma£210.24M0.00N/A-£33.00N/A
Allergy Therapeutics£57.29M9.84-£52.59M-£0.97N/A

Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Amryt PharmaN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.5% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Amryt Pharma Neutral
Allergy Therapeutics Neutral

Summary

Amryt Pharma and Allergy Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Allergy Therapeutics compare to Alliance Pharma?

Alliance Pharma (LON:APH) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Alliance Pharma has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.891, meaning that its stock price is 11% less volatile than the broader market.

Alliance Pharma has higher revenue and earnings than Allergy Therapeutics. Alliance Pharma is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A
Allergy Therapeutics£57.29M9.84-£52.59M-£0.97N/A

Alliance Pharma has a net margin of -6.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Alliance Pharma-6.00% -5.04% 5.98%
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Alliance Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Alliance Pharma Neutral
Allergy Therapeutics Neutral

66.3% of Alliance Pharma shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 12.0% of Alliance Pharma shares are owned by insiders. Comparatively, 3.5% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alliance Pharma beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Animalcare Group?

Animalcare Group (LON:ANCR) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Animalcare Group's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Animalcare Group Neutral
Allergy Therapeutics Neutral

Animalcare Group has a net margin of 5.70% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Animalcare Group5.70% 4.46% 2.97%
Allergy Therapeutics -85.46%409.00%-34.76%

Animalcare Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Animalcare Group£81.07M2.84£36.55M£3.6092.50
Allergy Therapeutics£57.29M9.84-£52.59M-£0.97N/A

Animalcare Group has a beta of 0.694, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.891, suggesting that its stock price is 11% less volatile than the broader market.

16.1% of Animalcare Group shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 30.1% of Animalcare Group shares are owned by insiders. Comparatively, 3.5% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Animalcare Group beats Allergy Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

Export
MetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£563.60M£2.45B£6.25B£2.79B
Dividend Yield8.33%2.95%2.69%6.13%
P/E Ratio-9.185.2021.07364.76
Price / Sales9.841,770.63556.3287,562.76
Price / Cash3.6610.1842.3127.85
Price / Book90.1910.679.787.67
Net Income-£52.59M£20.70B£3.56B£5.88B
7 Day Performance-1.11%-0.14%-0.18%6.53%
1 Month Performance-13.17%4.15%4.95%9.76%
1 Year Performance28.99%16.47%28.44%75.45%

Allergy Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 8.90
+4.7%		N/A+25.0%£563.60M£57.29MN/A612
INDV
Indivior
N/AGBX 1,238
+1.6%		N/A+33.9%£1.93B£1.40BN/A1,000
HCM
HUTCHMED
N/AGBX 180
+2.9%		N/A-13.9%£1.55B£548.51M3.401,760
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290
APH
Alliance Pharma
N/AGBX 64.70
flat		N/AN/A£350.32M£183.50MN/A91,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AGY) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel